TABLE 2.
Clinical and bacteriologic success rates at TOC
| Efficacy measurement (population, time point) | No. of responses/total no. in population (%)
|
||
|---|---|---|---|
| Sparfloxacin | Ofloxacin | 95% CIa | |
| Clinical success rate | |||
| All-treatedb | 181/196 (92.3) | 196/207 (94.7) | −7.2, 2.5 |
| Clinically evaluable | 173/187 (92.5) | 185/196 (94.4) | −6.8, 3.1 |
| Bacteriologically evaluable | 89/93 (95.7) | 74/81 (91.4) | −3.0, 11.7 |
| Bacteriologic success rate | |||
| All-treatedc | 111/116 (95.7) | 100/103 (97.1) | −6.3, 3.5 |
| Bacteriologically evaluable | 91/93 (97.8) | 80/81 (98.8) | −4.7, 2.9 |
| Overall success rate | |||
| All-treatedc | 105/114 (92.1) | 91/102 (89.2) | −4.9, 10.7 |
| Bacteriologically evaluabled | 88/93 (94.6) | 73/81 (90.1) | −3.5, 12.5 |
a
CI, confidence interval (sparfloxacin-ofloxacin).
b
Excluding patients with indeterminate response.
c
Baseline pathogen at ≥105 CFU/ml.
d
Primary efficacy parameter.